Valuation-driven coverage across software, energy, and medtech.

Report 01 · Software · CSU:CN · TSX

Constellation Software (CSU): acquisition-compounding machine; ROIC on capital deployment is the investment case.

Buy. Serial acquirer of vertical market software with 30%+ sustained ROIC on deployed capital; high gross revenue retention and a still-fragmented addressable acquisition universe support durable long-duration compounding.

Investment thesis: CSU's edge is not simply "buy and hold"; it is a repeatable acquisition methodology applied to niche vertical market software (VMS) businesses at disciplined IRR thresholds, a channel that remains structurally uncrowded relative to the breadth of the addressable VMS universe. Our analysis supports three convictions: (1) gross revenue retention of 95%+ across the portfolio is the FCF quality anchor: CSU does not need growth to generate cash; (2) ROIC on cumulative acquired capital has held above 30% for a decade, the clearest signal of acquisition discipline; (3) the Topicus spin-out demonstrates that the model scales internationally without ROIC dilution, extending the runway for capital deployment. At current prices, investors are paying a mid-20s FCF multiple for a business that can compound intrinsic value at 20%+ annually if deployment velocity is maintained.

Key drivers: (1) M&A pipeline depth: fragmented VMS market globally; addressable universe of acquisition targets still counts in the thousands. (2) Topicus growth: European VMS penetration still early; adds an independent capital deployment vehicle with separate reporting. (3) Operating leverage: organic growth of 5–8% on a maintenance-heavy revenue base drops to FCF at high incremental margins. Key risks: acquisition multiple inflation in VMS (crowded by PE entrants), deterioration in renewal rates below 90%, management succession at Vela Trading (key operator).

Valuation: Price target based on a sum-of-the-parts applying 25× NTM owner earnings to the legacy CSU portfolio plus a 20× multiple on Topicus (faster growth, higher reinvestment). Bull case assumes sustained 30%+ ROIC and accelerating deployment; bear case reflects acquisition slowdown and multiple compression to 18× FCF.

Report 02 · Energy · CNQ:CN · TSX

Canadian Natural Resources (CNQ): long-life, low-decline oil sands; premium asset quality, balanced valuation.

Hold. CNQ is Canada's highest-quality oil sands franchise: 31-year proved RLI, 26 consecutive years of dividend growth, C$15.5bn AFF in FY2025. Current price at C$66 already reflects the premium; blended target of C$61.25 implies 7.3% downside.

Investment thesis: CNQ's integrated oil sands and conventional asset base generates sector-leading FCF underpinned by one of the lowest sustaining-capex profiles in oil sands (~C$9–14/boe). The capital returns framework is tiered by net debt milestone: at Q1'26 net debt of C$16.2bn the company has entered Milestone 2, directing 75% of excess FCF to buybacks, with a path toward C$13bn (Milestone 3: 100% FCF to returns) within 12–18 months at base-case WTI. FY2025 production of 1.57 MMBOE/d reached a record, and FY2026 guidance of 1.615–1.665 MMBOE/d with C$6.0bn capex implies continued FCF accretion.

Hold rationale: CNQ trades at 10.6× EV/EBITDA, a 25% premium to the Canadian energy peer median of ~8.5×. This premium is justified by the reserve-life advantage and returns discipline, but already embedded in the current price. Our blended valuation (40% EV/EBITDA peer-median, 40% P/FCF, 20% consensus) supports C$61.25. We would become constructive at C$55–58. Key risks: WTI below $55, WCS differential widening above $20, carbon policy escalation, pipeline disruption.

Report 03 · Medtech · ISRG:US · NASDAQ

Intuitive Surgical (ISRG): tariff noise masking a durable recurring-utilization platform.

Buy. Tariff headwinds (~US$250M, FY2026-specific per management) are masking 84–86% recurring revenue, da Vinci 5 replacement-cycle tailwinds, and 16–19% OUS procedure growth. At US$421, 31% below the 52-week high, the risk/reward is compelling.

Investment thesis: ISRG's 11,400+ installed da Vinci systems generate recurring I&A and service revenue at ~68–70% gross margins, compounding as procedures grow 15–18% annually. Da Vinci 5, at 54% of Q1'26 placements, is driving I&A revenue per procedure expansion from $1,810 toward $1,940 over the next 2–3 years. The Ion endoluminal platform (1,041 systems; procedures +39%) adds a second compounding platform. ISRG holds a net cash position of ~US$10.2bn with no financial debt. Our FY2026E non-GAAP EPS of US$10.20 (+14%) and FY2027E of US$11.80 (+16%) support the thesis that tariff headwinds are transitional, not structural.

BUY rationale: At US$421 (~56× NTM FCF), we are not calling for multiple expansion; we are calling for earnings growth of 14–16% to compound to a US$582 price. Competitive risk (Medtronic Hugo, J&J Ottava) is 5–7 years from meaningful market share displacement; ISRG's surgeon-training moat with 10,000+ certified surgeons globally is not replicable short-term. Key risks: multiple compression, tariff escalation beyond guidance, hospital capex cycles, reimbursement pressure.

Report 04 · Materials / Gold · AEM · TSX & NYSE

Agnico Eagle Mines (AEM): premier low-risk gold franchise, with the quality already in the price.

Hold. Agnico is the highest-quality senior gold producer: 3.45 Moz at US$1,339 AISC in 2025, a record 55.4 Moz reserve base, and assets concentrated in Canada, Finland, and Australia. Record free cash flow and a 12.5% dividend increase reward holders, but at ~US$155 a premium multiple and a flat production profile leave a balanced risk/reward.

Investment thesis: Agnico pairs the lowest geopolitical-risk asset base among senior gold producers with sector-leading execution. FY2025 payable production of 3.45 Moz at total cash costs of US$979/oz and AISC of US$1,339/oz turned the gold rally into record free cash flow and US$1.4bn of shareholder returns, capturing roughly 95% of the gold-price move at the margin. Proven and probable reserves rose 2% to a record 55.4 Moz and indicated resources rose 10% to 47.1 Moz, extending mine life across Detour Lake, Canadian Malartic and the Odyssey underground, and the Nunavut platform organically rather than by acquisition. Sustained debt reduction leaves the balance sheet near net-cash.

Hold rationale: The case is high quality and well understood. FY2026 guidance holds production flat at 3.3–3.5 Moz while AISC steps up to US$1,400–1,550 (midpoint US$1,475), close to 10% cost inflation that compresses incremental margin if gold stalls. At ~US$155 AEM trades at a premium P/NAV and EV/EBITDA to the senior gold peer set, a premium we view as earned on jurisdiction and execution but largely captured. We would turn constructive on a pullback toward US$135–140, or on evidence of per-share growth beyond the flat 2026–2028 plan. Key risks: a reversal in the gold price, AISC inflation above guidance, and the absence of organic volume growth.